Group 1 - The People's Bank of China has announced a one-time credit repair policy, allowing individuals to have overdue information removed from the financial credit information database if they repay overdue debts of up to 10,000 RMB by March 31, 2026 [1] Group 2 - In the next two weeks, 46 routes between China and Japan will cancel all flights, with a total of 2,195 flights canceled from mainland China to Japan by December 22, 2025, resulting in a cancellation rate of 40.4% [2] Group 3 - Four new stocks in Hong Kong experienced a collective drop on their first trading day, with Mindray Hospital falling nearly 50%, marking the worst performance for new stocks this year [4] Group 4 - The U.S. Secretary of State emphasized the importance of maintaining relations with China while continuing strong partnerships with Japan, indicating a balanced approach to U.S. policy in the Asia-Pacific region [3][10] Group 5 - Zhiyuan Robotics expects to achieve sales revenue exceeding 1 billion RMB this year, with plans for significant growth in robot shipments and revenue in the coming years [4] Group 6 - The State-owned Assets Supervision and Administration Commission of China is committed to deepening cooperation with Hong Kong to enhance its status as a financial center and support the internationalization of the RMB [6] Group 7 - The Ministry of Commerce announced temporary countervailing measures on imported dairy products from the EU, effective December 23, 2025 [10]

Group 1 - The Hong Kong IPO market experienced a collective downturn on December 22, 2025, with four newly listed stocks, including Impression Da Hong Pao (HK02695), Huaren Biotech-B (HK02396), Ming Kee Hospital (HK02581), and Nanhua Futures (HK02691), all facing significant declines, with Ming Kee Hospital dropping 49.46%, marking the worst debut performance of the year [1] - All four new stocks opened lower and continued to decline throughout the trading day, closing near their lowest prices. Ming Kee Hospital, which had an offering price of 9.34 HKD, closed at 4.73 HKD, resulting in a loss of 1,420 HKD per lot of 500 shares, surpassing the previous record decline of 47.67% set by Conch Cement Technology [1] - Impression Da Hong Pao, despite receiving a 3,400 times oversubscription and a pre-listing increase of 11% on the Futu platform, ultimately closed down 35.28% at 2.33 HKD, leading to a loss of 1,270 HKD per lot of 1,000 shares [1] Group 2 - Following the reform of the Hong Kong IPO pricing mechanism in August 2025, the new stock failure rate was only 7.14% from August to October, but it surged to 42.10% from November onwards, significantly exceeding the 30.23% rate observed in the first half of the year [2] - The core reason for this discrepancy is the misalignment between primary market pricing and secondary market risk appetite, with issuers often referencing A-share valuations while Hong Kong investors prioritize cash flow and dividend returns, compounded by increased pressure from southbound capital and smaller float sizes, leading to concentrated sell-offs post-listing [2] - The Hong Kong IPO market has reached a scale of 267.1 billion HKD this year, with potential to reclaim the top position globally for IPOs. However, ongoing fluctuations in Federal Reserve policy expectations and changes in cross-border capital flows indicate that the valuation restructuring in the Hong Kong new stock market is still ongoing, resulting in a more cautious sentiment among investors regarding new listings [2]

明基医院招股结果进一步显示，本次募资总额约6.26亿港元，净额约5.55亿港元。本次募资资金，计划用于医院扩建、智慧医院系统升级及并购储备。其 中，南京明基医院二期工程将强化区域医疗资源供给，提升智慧医疗服务能力，助力河西新城医疗配套升级。 据悉，作为建邺区重点民营医疗机构，南京明基医院位于河西大街71号，2008年开始运营，2022年获评三级甲等，为江苏省首家民营三甲医院。根据弗若 斯特沙利文的数据，以2024年总收入26.59亿元计，南京明基医院是中国第三大民营营利性综合医院，也是江苏省最大的民营营利性综合医院。此外，南 京明基医院还是中国首批国家胸痛中心认证单位、"全国健康管理示范基地"，拥有多个国家级及省级重点科室。 今年以来，南京企业 进军资本市场按下"加速键" 12月22日，明基医院集团股份有限公司（以下简称明基医院）成功在香港联交所主板挂牌上市，集资总额超6亿港元，为国际资本市场增添一股蕴含南京 基因的优质民营医院价值样本。 明基医院是中国内地大型民营营利性综合医院集团，旗下运营南京明基医院和苏州明基医院，是华东地区最大的民营营利性综合医院集团。截至今年6月 30日，明基医院两家医院总建筑面积合 ...

Market Overview - The Hong Kong stock market experienced fluctuations, with the Hang Seng Index closing up 0.43% at 25,801.77 points and a total trading volume of HKD 169.77 billion [1] - The market is currently in a left-side layout phase, with strong expectations for a spring rally, although there are supply and demand pressures towards the end of the year [1] Blue Chip Performance - Semiconductor company SMIC (00981) led blue-chip gains, rising 5.92% to HKD 68.9, contributing 27.67 points to the Hang Seng Index [2] - Other notable blue-chip performers included Zijin Mining (02899) up 5.3% and Pop Mart (09992) up 4.61%, while WuXi AppTec (02359) and Hang Lung Properties (00101) saw declines [2] Sector Highlights - Large technology stocks generally rose, with Alibaba up 0.76% and Tencent up 0.08% [3] - The metals sector saw significant gains, with gold prices surpassing USD 4,400 per ounce and LME copper prices nearing USD 12,000 per ton [4] - The new consumption sector was active, with companies like Mixue Group (02097) rising 10.13% following the opening of a new store in Los Angeles [6] Investment Opportunities - The storage and advanced process sectors are expected to see accelerated growth, benefiting domestic equipment manufacturers [5] - The AI and robotics sectors are gaining traction, with companies like Ubiquiti (09880) and others seeing increased orders and market interest [6][7] New Stock Listings - Four new stocks listed on the Hong Kong market faced significant declines on their debut, with Mindray Hospital (02581) dropping 49.46% [8] - China Duty Free Group (01880) saw a strong performance, rising 15.77% amid positive sales data from Hainan's duty-free shopping [9] Company-Specific Developments - Yujian (02432) faced downward pressure due to an upcoming lock-up expiration and a recent share placement [10]

Group 1 - The core viewpoint of the article highlights that Mingji Hospital (02581.HK) experienced a significant stock price drop of 49.46% on its first day of trading on the Hong Kong Stock Exchange, closing at HKD 4.72 per share [1] - Mingji Hospital is a private for-profit comprehensive hospital group operating two hospitals in Nanjing and Suzhou, with revenue primarily generated from inpatient and outpatient medical services [1] - In the first half of this year, Mingji Hospital reported a decline in both revenue and net profit, with total revenue approximately CNY 1.312 billion, a year-on-year decrease of 1.34%, and a net profit of approximately CNY 48.7 million, down 23.18% year-on-year [1]

Core Viewpoint - Four new stocks listed on the Hong Kong stock market experienced significant declines on their first trading day, marking a poor performance for new listings in 2023 [1] Group 1: Stock Performance - Ming Kee Hospital (02581.HK) fell by 49.46%, the largest drop among the new listings [1] - Impression Da Hong Pao (02695.HK) decreased by 35.28% [1] - Huazhi Biotechnology (02396.HK) saw a decline of 29.32% [1] - Nanhua Futures (02691.HK) dropped by 24.17% [1] Group 2: Market Context - The decline of Ming Kee Hospital exceeded the previous worst first-day performance of 47.67% by Conch Cement Technology (02560.HK) on January 9, setting a new record for the worst debut performance of new stocks in Hong Kong this year [1]

中国经济网北京12月22日讯 明基医院集团股份有限公司（以下简称"明基医院"，02581.HK）今日 在港交所上市。明基医院开盘即破发，报6.5港元，截至收盘报4.72港元，跌幅49.46%。 | 發售股份及股本 | | | --- | --- | | 發售股份數目 | 67,000,000 | | 香港公開發售的最終發售股份數目 | 6,700,000 | | 國際發售的最終發售股份數目 | 60,300,000 | | 上市後已發行股份數目 | 311,945,001 | 最终发售价及分配结果公告显示，明基医院全球发售项下的发售股份数目67,000,000股股份，其中 香港发售股份数目6,700,000股股份，国际发售股份数目60,300,000股股份。 明基医院的联席保荐人、整体协调人、联席全球协调人、联席账簿管理人及联席牵头经办人为中国 国际金融香港证券有限公司、花旗环球金融亚洲有限公司，联席全球协调人、联席账簿管理人及联席牵 头经办人为中国信托商业银行股份有限公司，联席账簿管理人及联席牵头经办人为富途证券国际（香 港）有限公司、利弗莫尔证券有限公司、TradeGo Markets Limited、大 ...

Group 1 - The Hang Seng Index rose by 0.20%, gaining 51 points to close at 25,742 points, while the Hang Seng Tech Index increased by 0.89% [1] - China Duty Free Group (01880) surged by 12% as duty-free shopping on Hainan's first day of closure increased by 61% year-on-year [1] - Lithium stocks continued to rise, with Tianqi Lithium (09696) up over 5% due to expectations of resumption of production, and Ganfeng Lithium (01772) increasing by 4.84% [1] - Jiaxin International Resources (03858) rose over 10% to reach a new high, benefiting from a more than 220% increase in tungsten powder prices this year [1] - Spot gold reached a new historical high, with Goldman Sachs reaffirming a bullish outlook on gold, leading to significant gains in gold stocks such as Lingbao Gold (03330) up 6.8% and China Gold International (02099) up 6.2% [1] - The optical communication sector showed strong performance, with Huiju Technology (01729) rising over 13% due to breakthroughs in optical computing chips, and Changfei Optical Fiber (06869) increasing by 11.01% [1] - Chip stocks strengthened in early trading, with the National Integrated Circuit Investment Fund's third phase focusing on IC substrate fields, leading to a rise of over 7% for SMIC (00981) and 5% for Hua Hong Semiconductor (01347) [1] - Pony.ai-W (02026) increased by over 9%, achieving single-vehicle profitability in Guangzhou, with two models of its seventh-generation vehicle now in production [1] Group 2 - Guoxia Technology (02655) surged over 16% as the company enters a new phase of global development, focusing on deepening "AI+" core technology research in energy storage [2] - WanGuo Gold Group (03939) rose nearly 7%, with its subsidiary Jinling Mining expected to become a world-class gold mine [3] - Goldwind Technology (02208) increased by nearly 5% as domestic wind turbine bidding prices recovered, with institutions optimistic about the profitability recovery of wind turbine manufacturers [4] - Four new stocks listed all fell below their issue prices, with Impression Dahongpao (02695) dropping 25%, Mingji Hospital (02581) down 42%, and Huazhi Biotechnology-B (02396) declining over 8% [4]

Core Viewpoint - Ming Chi Hospital (2581.HK) experienced a significant drop on its first day of trading, falling over 43% to HKD 5.28, resulting in a market capitalization of HKD 1.64 billion, despite an IPO pricing of HKD 9.34 and a public offering subscription rate of 6.28 times [1] Financial Performance - The company's revenue increased from HKD 2,336.4 million in 2022 to HKD 2,687.6 million in 2023, with a slight decrease projected to HKD 2,659.0 million in 2024 [1] - The gross profit margin improved from 16.4% in 2022 to 18.9% in 2023, with a forecasted decline to 18.1% in 2024 [1] - Net profit for the years 2022, 2023, and 2024 was reported at HKD 89.6 million, HKD 167.5 million, and HKD 108.9 million respectively, with net profit margins of 3.8%, 6.2%, and 4.1% for the same years [1]

Group 1: Stock Market Performance - The Hang Seng Index rose by 0.20%, gaining 51 points to close at 25,742 points, while the Hang Seng Tech Index increased by 0.89% [1] - The Hong Kong stock market saw a trading volume of HKD 95.5 billion in the morning session [1] Group 2: Company Highlights - China Duty Free Group (01880) surged by 12% as duty-free shopping on the first day of Hainan's closure increased by 61% year-on-year [1] - Tianqi Lithium (09696) rose over 5% due to expectations of resumption of production following environmental assessment information disclosure [1] - Ganfeng Lithium (01772) increased by 4.84% [1] - Jiaxin International Resources (03858) climbed over 10%, reaching a new high, benefiting from a more than 220% increase in tungsten powder prices this year [1] - Gold stocks performed well, with Lingbao Gold (03330) rising by 6.8% and China Gold International (02099) increasing by 6.2% as spot gold reached a historical high [1] - Huizhu Technology (01729) surged over 13% due to breakthroughs in optical computing chip technology [1] - Zhongke Semiconductor (00981) rose over 7% as the National Integrated Circuit Investment Fund's third phase focuses on IC substrate [1] - Pony.ai-W (02026) increased by over 9%, achieving single-vehicle profitability in Guangzhou with two models of its seventh-generation vehicle in production [1] - Guoxia Technology (02655) surged over 16% as the company enters a new phase of global development, focusing on "AI+" energy storage core technology [2] - WanGuo Gold Group (03939) rose nearly 7% as its subsidiary Jinling Mining is expected to become a world-class gold mine [3] - Goldwind Technology (02208) increased nearly 5% as domestic wind turbine bidding prices recover, with institutions optimistic about the profitability of wind turbine manufacturers [4] Group 3: IPO Performance - Four new stocks listed all experienced declines, with Impression Dahongpao (02695) dropping by 25%, Mingji Hospital (02581) falling by 42%, and Huazhi Biotechnology-B (02396) decreasing by over 8% [4]